The global transdermal patch market, projected to grow from $1.61 billion in 2024 to $2.35 billion by 2029, is expected to reach $18 billion by 2030, expanding at a CAGR of 7.8%. The U.S. leads with a ...

Restless legs syndrome (RLS) is a chronic, usually idiopathic disorder characterized by uncontrollable urges to move the legs or arms at night along with unpleasant sensations in the affected limbs.

The global market for transdermal patches is experiencing rapid transformation, providing advanced solutions for the controlled administration of therapeutic agents across a range of medical ...

TOKYO, March 31, 2025 /PRNewswire/ -- Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the ...

EE: Ethinyl estradiol; LNG: Levonorgestrel; OC: Oral contraceptive; RR: Relative risk; VTE: Venous thromboembolism. Transdermal contraceptive patches provide a more convenient delivery system for ...

Sparsha Pharma International Private Limited, a leading transdermal patch manufacturing company based in Hyderabad, continues to advance its mission to create and maintain a sustainable pipeline of ...